{
  "docId": "019de075-2fc9-715d-b6e1-faa3fd3ed1eb",
  "docSlug": "be407bbae8f9e005c3f7268aea2b4f13",
  "documentTitle": "NeuroSense Therapeutics | Investor Presentation Deck | 34 slides",
  "authorId": "neurosense-therapeutics",
  "authorName": "NeuroSense Therapeutics",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-06-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 3,
  "pageCount": 34,
  "prevPage": 2,
  "nextPage": 4,
  "slideType": "roadmap",
  "function": "plan_implementation",
  "density": "balanced",
  "nDataPoints": 0,
  "notes": "The slide uses a standard drug development pipeline visualization.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de075-2fc9-715d-b6e1-faa3fd3ed1eb/3",
  "deckHref": "/decks/019de075-2fc9-715d-b6e1-faa3fd3ed1eb",
  "deckJsonHref": "/decks/019de075-2fc9-715d-b6e1-faa3fd3ed1eb.json",
  "deckAnchorHref": "/decks/019de075-2fc9-715d-b6e1-faa3fd3ed1eb#slide-3",
  "components": [
    {
      "bbox": {
        "h": 0.06,
        "w": 0.85,
        "x": 0.07,
        "y": 0.385
      },
      "kind": "diagram",
      "text": "Clinical development pipeline stages from Discovery to NDA",
      "attrs": null,
      "subkind": "timeline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "e933a282-1472-47f7-9714-e714ad6d2da9",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.35,
        "w": 0.15,
        "x": 0.07,
        "y": 0.45
      },
      "kind": "list",
      "text": "ALS, Alzheimer's, Parkinson's",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "3d149660-6c35-43ae-81fc-37fc4a722065",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.35,
        "w": 0.15,
        "x": 0.79,
        "y": 0.45
      },
      "kind": "paragraph",
      "text": "Topline data from Phase 2b placebo-controlled clinical trial expected in Q4 2023. Commencement of Phase 2 placebo-controlled clinical trial expected in H2 2023. Exploring potential co-development with collaborators that have core focus in Parkinson's",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "e4f43e00-17d6-4391-82d2-8a43c68880ba",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.65,
        "x": 0.08,
        "y": 0.12
      },
      "kind": "title",
      "text": "NeuroSense is a Leader in Developing Novel Combination Therapies for ALS and Other Neurodegenerative Diseases",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "db5a34bd-fb84-4b2e-a3e3-3075ef0d5b26",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [
    {
      "name": "gantt-chart",
      "slug": null,
      "matchId": "23d492dc-a375-477c-8451-033dd139a1ad",
      "evidence": "Pipeline visualization showing progress across clinical stages",
      "confidence": 0.9
    }
  ],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}